- Home
- CHNR vs SILO Comparison
CHNR vs SILO Comparison
Compare CHNR & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- SILO
- Stock Information
- Founded
- CHNR N/A
- SILO 2010
- Country
- CHNR China
- SILO United States
- Employees
- CHNR N/A
- SILO N/A
- Industry
- CHNR Precious Metals
- SILO Apparel
- Sector
- CHNR Basic Materials
- SILO Consumer Discretionary
- Exchange
- CHNR Nasdaq
- SILO Nasdaq
- Market Cap
- CHNR 5.3M
- SILO 5.9M
- IPO Year
- CHNR 1995
- SILO N/A
- Fundamental
- Price
- CHNR $5.09
- SILO $0.70
- Analyst Decision
- CHNR
- SILO
- Analyst Count
- CHNR 0
- SILO 0
- Target Price
- CHNR N/A
- SILO N/A
- AVG Volume (30 Days)
- CHNR 67.8K
- SILO 941.5K
- Earning Date
- CHNR 11-11-2025
- SILO 11-11-2025
- Dividend Yield
- CHNR N/A
- SILO N/A
- EPS Growth
- CHNR N/A
- SILO N/A
- EPS
- CHNR N/A
- SILO N/A
- Revenue
- CHNR N/A
- SILO $72,102.00
- Revenue This Year
- CHNR N/A
- SILO $1.86
- Revenue Next Year
- CHNR N/A
- SILO N/A
- P/E Ratio
- CHNR N/A
- SILO N/A
- Revenue Growth
- CHNR N/A
- SILO N/A
- 52 Week Low
- CHNR $3.16
- SILO $0.41
- 52 Week High
- CHNR $9.04
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- CHNR 66.33
- SILO 54.08
- Support Level
- CHNR $3.87
- SILO $0.58
- Resistance Level
- CHNR $5.10
- SILO $0.83
- Average True Range (ATR)
- CHNR 0.42
- SILO 0.05
- MACD
- CHNR 0.10
- SILO 0.01
- Stochastic Oscillator
- CHNR 93.47
- SILO 48.39
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.